{"protocolSection":{"identificationModule":{"nctId":"NCT06474819","orgStudyIdInfo":{"id":"DEEP"},"organization":{"fullName":"Institut d'Investigació Biomèdica de Bellvitge","class":"OTHER"},"briefTitle":"Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy","officialTitle":"Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy","acronym":"DEEP"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-02","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-01-02","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-19","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Andrea Di Marco","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Institut d'Investigació Biomèdica de Bellvitge"},"leadSponsor":{"name":"Institut d'Investigació Biomèdica de Bellvitge","class":"OTHER"},"collaborators":[{"name":"Fundació La Marató de TV3","class":"OTHER"},{"name":"Hospital Universitari de Bellvitge","class":"OTHER"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUsExport":true},"descriptionModule":{"briefSummary":"Multicenter randomized controlled trial which will include patients with left ventricular ejection fraction \\>50% requiring a first implant of a cardiac pacemaker with expected high pacing percentages.\n\nPatients will be randomized 1:1 to right ventricular apical pacing vs left septal or deep septal pacing. The primary endpoint will be pacing-induced cardiomyopathy during the first year of follow-up."},"conditionsModule":{"conditions":["Complete Heart Block","Second Degree Atrioventricular Block Möbitz Type II"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":326,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"deep","type":"EXPERIMENTAL","description":"The ventricular lead will be penetrated into the basal interventricular septum aiming at left septal pacing and, if not possible, at least deep septal pacing with a paced QRS duration \\<=140ms.","interventionNames":["Device: Pacemaker implant"]},{"label":"Apex","type":"ACTIVE_COMPARATOR","description":"The ventricular lead will be placed in the right ventricular apex.","interventionNames":["Device: Pacemaker implant"]}],"interventions":[{"type":"DEVICE","name":"Pacemaker implant","description":"All patients in the study will have a clear indication for a permanent pacemaker. The type of device (single or dual chamber) will be chosen as per clinical practice. The only difference between the two groups of the study will be the position of the ventricular lead.","armGroupLabels":["Apex","deep"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Pacing-induced cardiomyopathy","description":"Decrease in the left ventricular ejection fraction (LVEF) by \\>10% as compared to the LVEF before pacemaker implant and final LVEF\\<45%.","timeFrame":"12 months"}],"secondaryOutcomes":[{"measure":"LVEF during follow-up","description":"To compare the mean or median (depending on distribution) LVEF before and one year after pacemaker implant in the two groups.","timeFrame":"12 months"},{"measure":"Mitral and tricuspid regurgitation","description":"To compare the degree of mitral and tricuspid regurgitation before and one year after pacemaker implant in the two groups.","timeFrame":"12 months"},{"measure":"New York Heart Association (NYHA) class","description":"To compare the NYHA class one year after pacemaker implant in the two groups.","timeFrame":"12 months"},{"measure":"Brain Natriuretic Peptide levels","description":"To compare the N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels one year after pacemaker implant in the two groups.","timeFrame":"12 months"},{"measure":"heart failure","description":"Comparison of heart failure (HF) events in the first year after pacemaker implant in the two groups. HF events will be: hospitalizations for heart failure, emergency department or day-hospital visits for heart failure, heart failure symptoms requiring the initiation of diuretic therapy.","timeFrame":"12 months"}],"otherOutcomes":[{"measure":"Complications","description":"Complications related to the ventricular lead","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* First implant of a single-chamber or dual chamber pacemaker due to persistent bradycardia associated with high degree atrio-ventricular (AV) block (complete AV block or second degree type II AV block), with second-degree type I AV block (symptomatic or associated with intra-hisian or infra-hisian block), or with atrial fibrillation with symptomatic slow ventricular rate (\\<45lpm).\n* LVEF\\>50% at echocardiography performed maximum 7 days before pacemaker implant.\n* Informed consent signature.\n\nExclusion Criteria:\n\n* Life expectancy \\<12 months\n* Severe cardiac valvular abnormality requiring intervention\n* Unstable Angina, Acute myocardial infarction, coronary revascularization, valvular surgery or valvular percutaneous intervention in the 90 days prior to pacemaker implant.\n* Inclusion in another trial which may influence the results of this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Andrea Di Marco, MD, PhD","role":"CONTACT","phone":"+34932 60 75 00","phoneExt":"8385","email":"adimarco@bellvitgehospital.cat"}],"overallOfficials":[{"name":"Andrea Di Marco, MD, PhD","affiliation":"IDIBELL and Hospital Universitario de Bellvitge","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hospital Vall d'Hebrón","city":"Barcelona","country":"Spain","contacts":[{"name":"Raquel Adeliño Recasens","role":"CONTACT"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital General Universitario de Castellón","city":"Castellón De La Plana","country":"Spain","contacts":[{"name":"Clara Gunturiz Beltrán","role":"CONTACT"}],"geoPoint":{"lat":39.98567,"lon":-0.04935}},{"facility":"Hospital Virgen de las Nieves","city":"Granada","country":"Spain","contacts":[{"name":"Manuel Molina Lerma","role":"CONTACT"}],"geoPoint":{"lat":37.18817,"lon":-3.60667}},{"facility":"Hospital La Fe","city":"Valencia","country":"Spain","contacts":[{"name":"Oscar Cano Perez","role":"CONTACT"}],"geoPoint":{"lat":39.46975,"lon":-0.37739}},{"facility":"Hospital Lozano Blesa","city":"Zaragoza","country":"Spain","contacts":[{"name":"Javier Ramos Maqueda","role":"CONTACT"}],"geoPoint":{"lat":41.65606,"lon":-0.87734}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The study protocol and the informed consent form will be available upon request during the whole duration of the study.","infoTypes":["STUDY_PROTOCOL","ICF"],"timeFrame":"During the whole duration of the study","accessCriteria":"Request to the principal investigator."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009202","term":"Cardiomyopathies"},{"id":"D000054537","term":"Atrioventricular Block"},{"id":"D000006327","term":"Heart Block"}],"ancestors":[{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000075224","term":"Cardiac Conduction System Disease"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M12154","name":"Cardiomyopathies","asFound":"Cardiomyopathy","relevance":"HIGH"},{"id":"M27765","name":"Atrioventricular Block","asFound":"Atrioventricular Block","relevance":"HIGH"},{"id":"M9415","name":"Heart Block","asFound":"Heart Block","relevance":"HIGH"},{"id":"M9419","name":"Heart Diseases","relevance":"LOW"},{"id":"M4453","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M1472","name":"Cardiac Conduction System Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}